Literature DB >> 25317237

Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Alessandro Antonelli1, Silvia Martina Ferrari1, Dilia Giuggioli1, Andrea Di Domenicantonio1, Ilaria Ruffilli1, Alda Corrado1, Silvia Fabiani1, Santino Marchi1, Clodoveo Ferri1, Ele Ferrannini1, Poupak Fallahi1.   

Abstract

Hepatitis C virus (HCV) infection and diabetes mellitus are two major public health problems that cause devastating health and financial burdens worldwide. Diabetes can be classified into two major types: type 1 diabetes mellitus (T1DM) and T2DM. T2DM is a common endocrine disorder that encompasses multifactorial mechanisms, and T1DM is an immunologically mediated disease. Many epidemiological studies have shown an association between T2DM and chronic hepatitis C (CHC) infection. The processes through which CHC is associated with T2DM seem to involve direct viral effects, insulin resistance, proinflammatory cytokines, chemokines, and other immune-mediated mechanisms. Few data have been reported on the association of CHC and T1DM and reports on the potential association between T1DM and acute HCV infection are even rarer. A small number of studies indicate that interferon-α therapy can stimulate pancreatic autoimmunity and in certain cases lead to the development of T1DM. Diabetes and CHC have important interactions. Diabetic CHC patients have an increased risk of developing cirrhosis and hepatocellular carcinoma compared with non-diabetic CHC subjects. However, clinical trials on HCV-positive patients have reported improvements in glucose metabolism after antiviral treatment. Further studies are needed to improve prevention policies and to foster adequate and cost-effective programmes for the surveillance and treatment of diabetic CHC patients.

Entities:  

Keywords:  Epidemiology; Hepatitis C virus infection; Pathogenesis; Prevention; Treatment; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Year:  2014        PMID: 25317237      PMCID: PMC4138583          DOI: 10.4239/wjd.v5.i5.586

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  271 in total

1.  Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase.

Authors:  Jamel Mankouri; Philip R Tedbury; Sarah Gretton; Mair E Hughes; Stephen D C Griffin; Mark L Dallas; Kevin A Green; D Grahame Hardie; Chris Peers; Mark Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes.

Authors:  Dimitrios-Petrou Bogdanos; Eirini I Rigopoulou
Journal:  Diabetes Res Clin Pract       Date:  2006-11-21       Impact factor: 5.602

Review 3.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

4.  Hepatitis C antibody and transaminase activities in blood donors.

Authors:  C Morgan; C Hyland; I F Young
Journal:  Lancet       Date:  1990-04-14       Impact factor: 79.321

5.  Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.

Authors:  Masanori Yamazaki; Ai Sato; Teiji Takeda; Mitsuhisa Komatsu
Journal:  Intern Med       Date:  2010-03-01       Impact factor: 1.271

6.  Diabetes mellitus and interferon therapy.

Authors:  L Frankart; D Lejeune; J Donckier
Journal:  Diabet Med       Date:  1997-05       Impact factor: 4.359

Review 7.  The role of TNFalpha and TNF receptors in obesity and insulin resistance.

Authors:  G S Hotamisligil
Journal:  J Intern Med       Date:  1999-06       Impact factor: 8.989

8.  Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China.

Authors:  Li-Fen Wang; Chi-Hong Wu; Yuan Shan; Xiao-Hong Fan; Na Huo; Hai-Ying Lu; Xiao-Yuan Xu
Journal:  Chin Med J (Engl)       Date:  2011-01       Impact factor: 2.628

9.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

10.  Effect of interferon on glucose tolerance and insulin sensitivity.

Authors:  V A Koivisto; R Pelkonen; K Cantell
Journal:  Diabetes       Date:  1989-05       Impact factor: 9.461

View more
  30 in total

Review 1.  Management of patients with hepatitis C infection and renal disease.

Authors:  Chalermrat Bunchorntavakul; Monthira Maneerattanaporn; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2015-02-27

2.  Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.

Authors:  Ayush Jain; Bhupinder Singh Kalra; Siddharth Srivastava; Shalini Chawla
Journal:  Indian J Gastroenterol       Date:  2019-02-02

3.  Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.

Authors:  Sunil Taneja; Sunil Tohra; Ajay Duseja; Radha Krishan Dhiman; Yogesh Kumar Chawla
Journal:  J Clin Exp Hepatol       Date:  2016-08-18

Review 4.  Diabetic aggravation of stroke and animal models.

Authors:  Ashish K Rehni; Allen Liu; Miguel A Perez-Pinzon; Kunjan R Dave
Journal:  Exp Neurol       Date:  2017-03-06       Impact factor: 5.330

5.  Cell-autonomous cytotoxicity of type I interferon response via induction of endoplasmic reticulum stress.

Authors:  Chrysovalantou Mihailidou; Athanasios G Papavassiliou; Hippokratis Kiaris
Journal:  FASEB J       Date:  2017-08-17       Impact factor: 5.191

6.  Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Authors:  Elise J Smolders; Angela Colbers; Clara T M M de Kanter; Kirsten Velthoven-Graafland; Leonie T Wolberink; Noor van Ewijk-Beneken Kolmer; Joost P H Drenth; Rob E Aarnoutse; Cees J Tack; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-06-06       Impact factor: 4.335

7.  Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Authors:  Silvia Fabiani; Poupak Fallahi; Silvia Martina Ferrari; Mario Miccoli; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

8.  Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study.

Authors:  Kenneth A Lichtenstein; Rachel L D Hart; Kathleen C Wood; Samuel Bozzette; Kate Buchacz; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

9.  A SEVERE CASE OF HYPERGLYCEMIA IN A KIDNEY TRANSPLANT RECIPIENT UNDERGOING INTERFERON-FREE THERAPY FOR CHRONIC HEPATITIS C.

Authors:  L Iliescu; A Mercan-Stanciu; L Toma; E S Ioanitescu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

10.  Improper sharp disposal practices among diabetes patients in home care settings: Need for concern?

Authors:  Anindo Majumdar; Jayaprakash Sahoo; Gautam Roy; Sadishkumar Kamalanathan
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.